Addressing cancer control challenges in Africa

Liso-cel in r/r follicular lymphoma shows durable 3-year responses and favourable long-term safety

TKI chemotherapy and ponatinib improve survival outcomes in blast phase CML

Consolidation treatment delays do not compromise survival in MRD-negative adult ALL

SABCS 2025: Latest developments in multigene testing in early breast cancer

Multimodal AI model augments Oncotype DX in predicting distant recurrence in HR+/HER2 node negative BC

Non-TBI conditioning achieves positive results in MRD-negative CAYA B-ALL undergoing allogeneic HCT

Higher tumour-infiltrating lymphocytes predict better pathologic response in HER2-positive breast cancer

Dasatinib, prednisone, and blinatumomab combination shows promising outcomes in elderly patients with Ph+ ALL

Blinatumomab plus chemotherapy shows manageable toxicity in adults with Ph- B-ALL

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab